These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7893583)

  • 1. Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor, after multiple oral administration in humans.
    Wyld PJ; Grant J; Lippi A; Criscuoli M; Del Re G; Subissi A
    Br J Clin Pharmacol; 1994 Nov; 38(5):421-5. PubMed ID: 7893583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of idrapril calcium on tissue angiotensin-converting enzyme in rats.
    Becagli P; Lippi A; Criscuoli M; Breschi MC; Subissi A
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):27-32. PubMed ID: 7564361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.
    Zanchi A; Nussberger J; Criscuoli M; Capone P; Brunner HR
    J Cardiovasc Pharmacol; 1994 Aug; 24(2):317-22. PubMed ID: 7526067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral pharmacokinetics and pharmacodynamics of idrapril calcium, the prototype of a new class of angiotensin converting enzyme inhibitors, in humans.
    Criscuoli M; Subissi A; Coppini A; Capone P; Taddei S; Salvetti A
    J Hypertens Suppl; 1993 Dec; 11(5):S340-1. PubMed ID: 8158413
    [No Abstract]   [Full Text] [Related]  

  • 5. Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients.
    Taddei S; Ghiadoni L; Mattei P; Sudano I; Duranti P; Favilla S; Virdis A; Romagnoli A; Criscuoli M; Coppini A
    Eur J Clin Pharmacol; 1995; 48(5):339-43. PubMed ID: 8641320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
    Criscuoli M; Lippi A; Mengozzi G; Sardelli G; Subissi A; Giachetti A
    Drug Metab Dispos; 1993; 21(5):835-40. PubMed ID: 7902245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors.
    Subissi A; Criscuoli M; Sardelli G; Guelfi M; Giachetti A
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):139-46. PubMed ID: 1383623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response studies with idrapril in the rat heart during acute myocardial ischaemia and reperfusion.
    Riva E; Traquandi C
    Eur J Pharmacol; 1996 Oct; 312(3):293-300. PubMed ID: 8894611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductive metabolism and its role in the disposition of the hydroxamic angiotensin-converting enzyme inhibitor idrapril calcium in rat.
    Lippi A; Criscuoli M; Canali S; Subissi A
    Xenobiotica; 1996 May; 26(5):551-8. PubMed ID: 8736065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of rabbit lung angiotensin converting enzyme by idrapril.
    Lippi A; Criscuoli M; Sardelli G; Subissi A
    Biochem Pharmacol; 1993 Mar; 45(6):1358-62. PubMed ID: 8385462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
    Cawello W; Boekens H; Waitzinger J; Miller U
    Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic method with electrochemical detection for the determination of idrapril, a novel angiotensin-converting enzyme inhibitor, in biological matrices.
    Lippi A; Criscuoli M; Sardelli G; Subissi A
    J Chromatogr B Biomed Appl; 1994 Oct; 660(1):127-34. PubMed ID: 7858705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a new angiotensin-converting enzyme inhibitor (idrapril) in rats with left ventricular dysfunction after myocardial infarction.
    Jeremic G; Masson S; Luvara G; Porzio S; Lagrasta C; Riva E; Olivetti G; Latini R
    J Cardiovasc Pharmacol; 1996 Mar; 27(3):347-54. PubMed ID: 8907795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure.
    Squire IB; Macfadyen RJ; Lees KR; Hillis WS; Reid JL
    Br J Clin Pharmacol; 1994 Aug; 38(2):117-23. PubMed ID: 7981011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
    Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
    Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
    Bani M; Colantoni A; Guillaume M; Macchi F; Moroni G; Persiani S
    Br J Clin Pharmacol; 2000 Oct; 50(4):338-49. PubMed ID: 11012557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor.
    Patat A; Surjus A; Le Go A; Granier J
    Eur J Clin Pharmacol; 1989; 36(1):17-23. PubMed ID: 2537217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.
    Elliott HL; Macdonald NJ; Meredith PA; Reid JL
    Clin Pharmacol Ther; 1992 Mar; 51(3):260-5. PubMed ID: 1312002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN; Mauron C; Kaiser G
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
    Stangier J; Su CA; Roth W
    J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.